Market Trends– category –
-
Amgen Imdelltra: Phase 3 DeLLphi-305 results for ES-SCLC
BioSpace USA Overview Amgen's Imdelltra, combined with AstraZeneca's Imfinzi, reduced the risk of death by 58% compared to Imfinzi alone in first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC). The combin... -
pro-DALAP Platform: Yeast-Based Oral Dual GLP-1/GIP Agonist Evaluation
medRxiv USA Overview Researchers developed a Saccharomyces cerevisiae-based platform to deliver pro-DALAP, a dual GLP-1/GIP receptor agonist, via oral enteric-coated capsules. While in vitro and rat toxicology studies showed functionalit... -
Ultomiris: AstraZeneca’s FDA accelerated approval for IgAN
pharmaphorum UK Overview AstraZeneca has received FDA accelerated approval for Ultomiris (ravulizumab) to reduce proteinuria in patients with IgA nephropathy (IgAN) at risk of progression. This marks the drug's fifth disease indication a... -
Moderna and MSD: Melanoma Vaccine INTerpath-001 Phase 3 Results
pharmaphorum UK Overview Moderna and MSD reported that a personalized mRNA vaccine combined with Keytruda reduced the risk of recurrence or death by 42% in patients with resected stage IIB-IV melanoma. The combination achieved a 24-month... -
Bepirovirsen: GSK’s CHB Approval and Oligonucleotide Scale-up
PharmTech USA Overview The FDA has approved GSK's Hibsago (bepirovirsen) for chronic hepatitis B (CHB), demonstrating a 19% functional cure rate in pooled Phase III trials. This approval marks a shift for antisense oligonucleotides from ... -
Oral GLP-1 Agonists: FDA 2026 approval and manufacturing impact
NextGen Biologics USA Overview The July 2026 FDA approvals of two distinct oral GLP-1 receptor agonists, oral semaglutide and orforglipron, signify a regulatory inflection point in manufacturing modalities. Differences in their productio... -
Pebrilzo: Biocon Biologics’ HER2 biosimilar EMA specs for 2026
Pharma Journal India Overview Biocon Biologics' pertuzumab biosimilar, "Pebrilzo," for HER2-positive breast cancer, received a positive opinion recommending marketing authorization from the European Medicines Agency's (EMA) Committee for... -
UZEDY: Teva’s risperidone real-world data and cost specs
Teva (Press Release) Israel Overview Teva announced new real-world data at Psych Congress 2026, demonstrating that UZEDY® (risperidone extended-release injectable) for schizophrenia significantly improved treatment adherence and reduced ... -
Orforglipron: Eli Lilly oral GLP-1 vs injectable efficacy
Apps Script USA Overview Eli Lilly's investigational oral GLP-1 receptor agonist, Orforglipron, has shown potent weight loss and glycemic control effects in early clinical trials comparable to injectable GLP-1 drugs for type 2 diabetes a... -
Lonza to Build New Spray-Drying Facility in Oregon, US, Bolstering CDMO Capabilities in Particle Engineering for Enhanced Bioavailability
SWI swissinfo.ch Switzerland Overview Lonza, a leading Swiss CDMO, announced on September 10, 2026, plans to construct a new state-of-the-art manufacturing facility in Bend, Oregon, specialized in spray-drying technology. Expected to be ...
12